CG Oncology

CGON Lead: NDA Submitted 6 Biotech Distilled articles ↓

Most recent annual filing: 2026-02-15

Catalyst timeline

Creto BLA filing2026Creto BLA filing, 2026, notable
cretostimogene BLA HR filing4Q 2026cretostimogene BLA HR filing, 4Q 2026, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (1 active programs)

cretostimogene grenadenorepvec

Gene Therapy Target: Rb-E2F pathway, GM-CSF

Non-Muscle Invasive Bladder Cancer NDA Submitted intravesical Merck NCT04452591

Biotech Distilled coverage (6)

2026-08-07 UPDATE: CG Oncology (CGON) — The ATM Reloads at $72 🔒 Paid
2026-05-26 UPDATE: CG Oncology (CGON) — The COO Walks, the CEO Doubles Up 🔒 Paid
2026-05-16 UPDATE: CG Oncology (CGON) — The Gem Combo Clears the Bar 🔒 Paid
2026-05-09 UPDATE: CG Oncology (CGON) — Q1 2026 Status Check 🔒 Paid
2026-02-28 UPDATE: CG Oncology (CGON) - EoY Update 🔒 Paid
2026-01-23 CG Oncology (CGON): Scientific Deep Dive for Creto and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.